Pay in 4 interest-free payments of $6.06 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
To overcome these limitations, this review discusses a range of structural modifications, including N-terminal and C-terminal substitutions, fatty acid conjugation, and large molecule fusion technologies, which have collectively contributed to enhanced half-life, increased stability, improved receptor affinity, and retained or augmented bioactivity of GLP-1 analogs
RELATED TREATMENTS RELATED POSTS
Sci Transl Med 2013;5:209ra151.ArticlePubMed 52
Abbreviations: ACAT: acyl-CoA cholesterol acyltransferase
As the use of therapeutic peptides such as GLP-1 agonists becomes more common, it is vital to ensure the quality, safety, and efficacy of products intended for use in patients
30031-7/asset/bedae7b4-4f80-4686-b4c7-9c3f908ac1bd/main.assets/gr1.jpg)
